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Platinum compounds are widely used drugs in cancer treatments. Although DNA
is the biological target, reaction of platinum compounds with proteins is also potentially
significant. Our objective is to study the effects of leaving ligands on the relative
reactivity between 5'-GMP (guanosine 5' phosphate), a key DNA target, and N-Acetyl L-Methionine (N-AcMet), a key protein target. We have used NMR spectroscopy to
monitor reactions with N-AcMet and 5'-GMP added to a platinum complex to see which
products are formed preferentially. Previous research showed that both a non-bulky
complex such as [Pt(en)(D2O)2]2+ [en=ethylenediamine], and a bulky complex such as
[Pt(Me4en)(D2O)2]2+ [Me4en= N, N, N', N'-tetramethylethylenediamine] react more
quickly with 5'-GMP than with N-AcMet. To improve the activity of platinum
compounds in our current research, oxalates as leaving ligands are used. The results
suggest that [Pt(en)(Ox)] [Ox= oxalate] reacts faster with N-AcMet than with 5'-GMP.
Also, [Pt(Me4en)(Ox)] reacts slowly with 5'-GMP without N-AcMet and the reaction
favors N-AcMet when both ligands are added simultaneously. Interestingly, the
formation of the sulfur-oxygen chelate is slow enough to be observable in the oxalate
reaction; but the mono product is not independently observed in the dinitrate complex.
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I. INTRODUCTION

A. History
Cancer is a term used for diseases in which abnormal cells divide without control
and are able to invade other tissues. Cancer cells can spread to other parts of the body
through the blood and lymph systems. There are over 200 different known cancers that
effect humans. Many things may elevate the risk of cancer, including external factors
such as chemicals, radiation, environmental pollutants as well as internal factors like
mutations, hormones, and immune system conditions. Genetics account for
approximately 5-10% of cancers. The current treatment options are surgery, radiation,
chemotherapy, hormone therapy, biological therapy, and targeted therapy.1
The anticancer activity of cisplatin [PtCl2 (NH3)2] was first discovered by Barnett
Rosenberg in 1960. It is estimated that about 90% of testicular cancers are cured by
cisplatin and considered to play vital roles in treatment of ovarian, neck, bladder, and
cervical cancers.2 The clinical success of this drug initiated the use of metal compounds
for cancer.1 Following this, preparation and evaluation of thousands of platinum
compounds was started by scientists. However, only a few compounds have actually
entered into clinical use.1 Carboplatin {cis-(Pt(NH3)2(CBDCA)],CBDCA= 1,1cyclobutanedicarboxylic acid} and oxaliplatin {[Pt(oxalate)(1R,2R-chxn)], chxn=
cyclohexane-1,2-diamine} were a few of the drugs that were discovered, found to display
anticancer activity complementary to cisplatin.
The anticancer activity of platinum compounds were first investigated by
Rosenberg while he was studying electric field effects on bacterial growth. The
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electrodes that were made of platinum electrolyzed during the experiment and released a
platinum complex that caused inhibition of cell division in the bacterial rods. This
experiment was first carried out in Escherichia coli (E. coli) using ammonium chloride
buffer as an growth medium. Current was passed through inert platinum electrodes
immersed in the buffer.3,4 The result was that the E. coli cells began appearing long and
filamentous, similar to spaghetti, instead of their original sausage shape.4 From the
filamentation assay, the scientists hypothesized that the charged platinum complexes
were bactericidal and that this inhibition of cell division was not due to the electrical
current. It instead was due to the platinum hydrolysis products formed from the platinum
electrodes.3 Rosenberg also reported that the cis form of platinum (IV) complex
[PtCl4(NH3)2] was responsible for inhibition, whereas the trans form is ineffective. An
experiment was also carried out on swiss white mice injected with cis-[Pt(Cl4(NH3)2], a
platinum (IV) complex, and a platinum(II) complex cis-[Pt(Cl2(NH3)2]; the result was
that the large solid tumors in the mice were reduced in size and the mice survived.3,4 The
first clinical trials in 1972 gave very promising results. The experiments established
cisplatin’s efficacy as an anticancer drug, and the final approval of this drug in the United
States was in 1979. Since then, it has become one of the leading and most widely used
anticancer drugs. Better knowledge of the mechanism may lead to better administration
procedures and derivatives or analogues with superior properties.3
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Figure 1. Structure of Cisplatin
B. Synthesis of Cisplatin
The synthesis of cisplatin was carried out in 1845 by Michel Peyrone.1 Initially
the synthesis of cisplatin was unreliable, often producing impure products. Alterations
were made for improved purity of the product.1,4,5 The synthetic procedure of cisplatin is
explained in a schematic diagram in Fig 2. First, it involves potassium
tetrachloroplatinate (K2[PtCl4]) which is then converted to the tetraiodo analog K2[PtI4]
by the addition of potassium iodide (KI). The ammonia is added, forming a yellow
compound that is dried. After that, addition of an aqueous solution of silver nitrate
(AgNO3) to cis-[PtI2(NH3)2] causes insoluble AgI to precipitate. This is then filtered off.
Finally potassium chloride (KCl) is added to attain product of cisplatin cis[PtCl2(NH3)2].1,4
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Figure 2. Synthetic pathway of Cisplatin

C. Rate of Ligand-Exchange
xchange R
Reactions of Platinum Compounds
Ligand-exchange
exchange kinetics play aan important role in determining the anticancer
activity.6,7 The platinum ligand bond, having thermodynamic strength of a typical
coordination bond, is weaker than C
C-C, C-N or C-O, single, and double bonds. The
ligand- exchange behavior provides a reaction from minutes to days to allow to reach
reaches the target site despite various competing interactions
interactions. Certain ligand-exchange
ligand
reactions on platinum occur faster than others. 3 The trans-effect determines
determine the relative
reaction velocities
ities of platinum compounds. This concept was first introduced by
Chernyaev in the year 1926
1926.1 It states that, ligands in positions opposite (trans) to a
certain ligand in a platinum
latinum(II) compound are more or less rapidly exchanged
exchang compared
to others. This results in sequences of reactivity. For example, ligands trans to the
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following compounds in the sequence are more easily replaced: CN->phosphine>NO2->I>Br->CI->NH3>H2O.1,3,4
When the intermediate triiodo species K[PtI3(NH3)] reacts with the second
ammonia group there are two options as illustrated in Fig. 2, they are either displacement
of the iodo ligand that is trans to an ammonia ligand or displacement of the iodo ligand
that is trans to another iodo ligand. With an increase of the trans directing influence of
iodo ligand relative to ammonia ligand, the ligand trans to iodide is labile and can be
easily displaced to give cis configuration of the final product.1 Therefore ligands, in the
platinum compounds, determine the reactivity. In addition to the trans effect rule, Ptamine ligand bonds such as Pt(NH3)2+2 are usually very stable and Pt-H2O bonds and PtCl bonds are labile.3 Based on this concept, different platinum compounds are
synthesized by modifying their ligands to change their reactivity.3,4
D. Structure and Activity Relationship
Although cisplatin has clinical success, there are side-effects associated with the
cisplatin treatment such as nephrotoxicity, nausea, ototoxicity, and severe anemia.1,6 For a
drug to gain clinical approval it needs to have at least one unique clinical advantage over
cisplatin, such as reduced toxic side-effects. There are certain structural criteria for the
platinum compounds to show the antitumor activity (i.e. there is a relationship between
structure and activity).1
•

It is necessary that the compound should have two leaving groups that are cis with
respect to each another. 8,9 Leaving groups are those that are most easily lost. The
ease with which these leaving groups are lost will affect the activity as well as
toxicity of the compound. 8, 9
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•

The compound should be neutral with fewer alkyl substituents on the amine
ligands.1

•

The two amine groups should have cis geometry. The trans geometry will make
these compounds inactive for antitumor activity.1,3

•

Two cis-monodentate or one bidentate leaving group is required.9

•

The geometry of the complexes is either square planar or octahedral.9

•

The complexes should have at least one N-H group, which is required for
hydrogen bonding with the biological target.3,9

•

The leaving groups must be approximately 3.4 Å apart on the molecule.9

•

The rates of exchange of these groups should fall into restricted region.

Figure 3. General Structure of Platinum Compounds with Anti-Tumor Activity
X is the leaving group such as two chloro groups or a bidentate malonate ligand;
R=H or an alkyl substituent. (Fig.3)
The majority of the platinum compounds that are clinically successful have
adhered to this structure and activity criteria.1 Based on these structure activity
relationship, other platinum compounds with improved efficacy and less toxicity are
designed. Second and third generation platinum drugs such as carboplatin and oxaliplatin,
respectively to overcome cisplatin resistance have been introduced.

6

E. Analogs of Cisplatin
Carboplatin: Introduced in the year 1980, carboplatin is the second generation
platinum
m drug with lesser side
side-effects when compared to cisplatin; it is used in
combination therapy.6 It is also called cis
cis-diammine (1.1-cyclobutanedicarboxylato)
cyclobutanedicarboxylato)
platinum(II) and is mainly used in ovarian carcinoma, lung, head and neck cancer.
cancer 10-12
The
he cyclobutanedic
cyclobutanedicarboxylate (CBDCA) ring on carboplatin replaces the chloride
chl
leaving group of cisplatin
cisplatin. This replacement reduces the toxicity
ty of carboplatin when
compared to cisplatin as the rate of conversion to active species is slowed down.
down 1,6 These
drugs bond with the thiol sulfur atoms of proteins and amino groups in DNA.
DN The only
difference between cisplatin and carboplatin is that the carboplatin is a bigger molecule
with a dicarboxylate ligand which reduces the breakdown of agent metabolically and
lowers
owers the formation of toxic by
byproducts. Carboplatin is considered markedly
kedly less toxic
to the kidneys and nervous system than cisplatin and caused less nausea and vomiting
retaining equivalent anti-tumor
tumor activity.12

Figure 4. Structure of Carboplatin
Oxaliplatin: Oxaliplatin is a third generation platinum anticancer drug with a
diaminocyclohexane (dach) carrier ligand and an oxalate leaving group.111 Known also as
trans-R, R-1, 2-diaminocyclohexane
yclohexane oxalate platinum(II), it has decreased resistance in
7

cisplatin-resistant
resistant tumors. Oxaliplatin is the FDA approved drug with greater
reater efficacy in
treating colorectal cancer
cancer. Although it has similar DNA binding specificity to cisplatin,
the differences in cellular activity may be due to the differential recognit
recognition
ion of DNA
adducts. These differences may be due to the differences in uptake. Oxaliplatin produces
the similar type of inter and 11,2-GG intrastrand cross links as cisplatin, but has a different
spectrum of activity, mechanisms of aactions, and resistance than cisplatin and
carboplatin. However, the steric characteristics of non-hydrolysable
hydrolysable diaminocyclohexane
platinum adduct results in absence of cross resistance with cisplatin and carboplatin. The
main side-effects
effects of this drug are neurotoxicity, hematological toxicity, gastrointestinal
tract toxicity, and tubular necrosis.12

Figure 5. Structure of Oxaliplatin
F. Hydrolysis Reactions
eactions of Cisplatin
After administration of the cisplatin drug through injection or infusion in the
blood stream, a variety
riety of chemical reactions occur. A high concentration of chloride ions
(100
100 mM) suppresses hydrolysis to maintain the cisplatin in a neutral state.13 The
cisplatin that remains intact enters the tumor cells by diffusing
sing through the cell
membrane. With intracellular chloride concentration in the bloo
blood
d plasma being relatively
low (i.e. 4-20 mM), a chloro ligands of cisplatin is replaced by water to form a reactive,
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positively charged species that cannot readily leave the cell.13 The aqua ligand in cis
[PtCl(H2O)(NH3)2]+ is easily displaced. This allows the platinum atoms to bind to all
kinds of molecules inside the cell like DNA, RNA, proteins.3 In vitro, studies have shown
that this monoaquated platinum species is responsible for at least 98 percentage of
platinum binding to DNA within the cell nucleus.1 Of the DNA bases, guanine is the most
preferred.14
It is generally accepted that chloride hydrolysis is considered as a rate
determining step in the reaction of cisplatin with DNA.4 Significant losses of platinum
occur due to 50-70% of the administered platinum being excreted within 24 hours.4

Figure 6. Hydrolysis Reactions of Cisplatin
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G. Mechanism of Action of Platinum Anti-Tumor Drugs

O

N
NH

N
H

N

NH2

Figure 7. Guanine Residues of DNA

DNA as the Target
Specific interaction of cisplatin with DNA causes cell death.4 Aquated form of
cisplatin is considered more reactive than neutral cisplatin. Earlier studies have shown
that cisplatin preferentially binds at the nitrogen atoms of the nucleobases.4 To understand
this, studies have been conducted on binding preferences of nucleobases adenine (A),
guanine (G), and cytidine (C). In guanine, binding is possible at N7 and deprotonated N1
under alkaline conditions. Of all these binding modes those at N7 atoms of adenine and
guanine seem most compatible to DNA. This is thought to happen because the other sites
of A, G, and C are involved in the Watson-Crick base pairing of double helix.4 The
kinetic and competition studies conducted a decade ago have shown that guanine N7 has
a strong kinetic preference. Recent investigations have shown a Pt-N7 guanine bond is
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stable.3,4 The cis-Pt unit has two reactive sites and after binding to one guanine N7 a
second reaction with a nearby guanine can occur.4

Figure 8. Cisplatin Interaction with DNA
In carboplatin and oxaliplatin, the interactions with DNA occur at the position
where cyclobutane-1, 1-dicarboxylate (CBDCA) and oxalate ligands are attached to
platinum.15,16 This binding leads to a distortion of double helical structure of DNA thus
impairing its processing. The 1, 2 intra strand cross-links bend the DNA towards the
major groove exposing it to a wide shallow minor groove surface to which several
proteins bind. High mobility group proteins, or the HMG proteins, are the proteins which
are bound and cause cell cycle arrest, cell death, replication inhibition, and transcription
inhibition.13

Figure 9. Guanosine 5'-Monophosphate
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H. Preference of Platinum(II) Complexes for Guanine over Adenine
Previous results from the experimental observations suggest that the guanine is
the preferred reactant for platination.17 The N7 platination of guanine is both
thermodynamically and kinetically more favorable. A strong hydrogen bond between the
hydrogen of ammine ligand on platinum and the oxo group at C6 position of guanine
stabilize the platinum-guanine adduct. In comparison to the platinum-adenine adduct, this
results in 50% of the differential energy when the Pt-chloroaqua complex is the reactant.
The Pt-adenine adduct serves as the hydrogen bond donor and is energetically
unfavorable compared to an isomer where the amino functionality on the C6 position acts
as hydrogen donor to the chlorine ligand. If the diaqua complex is used as platination
agent, both the kinetic and thermodynamic preferences for guanine are increased
dramatically to 9.6 and 7.4 Kcal/mol respectively.17 Therefore guanine is preferred with
higher selectivity if diaqua complex is the active platinum (II) complex to bind.
I. Reaction of Platinum Complexes with Proteins
DNA is not the only target for platinum complexes; binding to proteins also
occurs.3 Studies have shown that one day after cisplatin administration, 65 to 98% of the
platinum in blood plasma is protein bound and significant protein adducts are formed.18,19
The reaction of platinum complexes with proteins results in formation of protein adducts,
which may be responsible for side-effects and drug resistance. In amino acids, sulfur
donor residues (Cysteine, Methionine) are primary targets owing to the relative softness
of platinum.21 Platinum also binds to the lone pairs of nitrogen atoms which occur in
amino acids in the absence of S-donor ligands.20
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Due to cisplatin’s affinity for sulfur ligands, reaction with peptides and proteins at
cysteine and methionine residues is common.18 Many studies have utilized
zed the amino acid
N-Acetyl –L-Methionine (N-AcMet),
AcMet), which has an amide nitrogen and is the
representative of internal methionine residue in peptide or protein to study the reactivity
21-22
of platinum complexes.21
Research has been conducted to study the intermolecular
int
and

intramolecular competition reactions to verify the binding preference of platinum in
presence of both sulfur grou
groups and N7 atoms of nucleobases.23-25 It was shown that
platinum reaction with methionine and related ligands is kinetically fav
favored
ored whereas the
reaction of platinum with guanine is thermodynamically favored.18,24,25 Sulfur group
reactivity with platinum complexes may act as a reservoir for platinum to form active
act
intermediates which result in platination of N7 position of DNA.9 It is, therefore,
therefore
important to better understand the interaction of platinum complexes with DNA and
proteins and to determine what factors affect the rates of reaction.18

Figure 10.. Structure of N-Acetyl-L-Methionine (N-AcMet)
AcMet)
Previous studies were focused on [Pt(Me4en)(D2O)2]+2 (Me4en=N, N, N', N'tetramethylethylenediamine)
enediamine) as a bulky platinum diamine complex. [Pt(en)(D2O)2]+2
(en=ethylenediamine) a less bulky ligand
ligand, was used to represent the diamine ligands of
cisplatin and carboplatin.
n. NMR spectroscopy monitored reactions where N-AcMet and
5'-GMP
GMP are added to platinum complexes at pH 4. It was analyzed from the studies
studie that

13

the [Pt(en)(D2O)2]+2 reacts more quickly than [Pt(Me4en)(D2O)2]+2 as expected.18
Although both complexes showed good reactivity with 5'-GMP, [Pt(en)(D2O)2]+2
complex favors reaction with 5'-GMP because of hydrogen bonding of the en ligand with
the 5'-phosphate. In contrast, reactivity of [Pt(Me4en)(D2O)2]+2 is disfavored with NAcMet due to steric clashes.16 Because the bulk had little effect on N-AcHis (NAcetylhistidine), His residues may be favored reaction over methionine residues in
protein reactions18
Present research focuses on modifying the platinum(II) complexes with oxalates
as a leaving groups and ethylenediamine as ligands. [Pt(en)(Ox)] represents a less bulkier
complex where as [Pt(Me4en)(Ox)] is used as bulkier complex. Both compounds feature
a square planar coordination complex and are classified as alkylating agents and a
coordination complex.
Oxalates are mainly preferred as they are very good water soluble leaving ligands
and are used by oxaliplatin. The features for the bidentate ligand, ethylenediamine, would
be less steric bulk and symmentry with two monodentate ammine ligands of cisplatin.
Proton NMR spectroscopy has been utilized to monitor the competition reactions
in which N-Acetyl-L-Methionine (N-AcMet) and Guanosine-5'-mono-phosphate (5'GMP) are added to platinum complexes to see which products are formed at pH-4.
Different ratios of 5'-GMP and N-AcMet are reacted with platinum to maintain the
constant ratio of platinum (II) complexes at pH 4.
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II. MATERIALS AND METHODS
A. Materials Used
The following items were purchased from Sigma Aldrich: Potassium
tetrachloroplatinate (II) (K2PtCl4), silver nitrate (AgNO3), dichloro (ethylenediamine)
platinum(II) (H2NCH2CH2CH2NH2)PtCl2), deuterium oxide (D2O), N-Acetyl -LMethionine (N-AcMet), (CH3SCH2CH2CH(NHCOCH3)CO2H), guanosine 5'- monophosphate dehydrate (5'-GMP), (C10H14N5 O8P), oxalic acid (anhydrous) (C2H2O4), silver
oxalate (Ag2C2O4).
B. Nuclear Magnetic Resonance Spectroscopy (NMR)
A JEOL Eclipse 500 MHz Nuclear Magnetic Resonance spectrometer was
utilized. 1H NMR spectroscopy was used to characterize the products and to analyze the
rate of the product formation.
C. Synthesis of [Pt(Me4en)(Ox)]
In this synthesis, 83 mg of potassium tetrachloroplatinate(II) (98%) is added to
5 mL of water in a round bottom flask. 30 µL of N, N, N', N 'tetramethylethylenediamine and 5 mL of methanol were combined in a beaker. This
mixture is added drop-wise to the potassium tetrachloroplatinate mixture, and allowed to
stir for 24 hours. The obtained solid is collected through gravity filtration and then dried.
Preparation of Silver Oxalate
A sample of 450 mg of oxalic acid and 1690 mg of silver nitrate are added in an
amber vial. A 20 mL deionized water was added and allowed to stir for one hour. The
insoluble silver oxalate was collected by vacuum filtration.
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The Final Step in the Synthesis of [Pt(Me4en)(Ox)]
Silver oxalate is combined with the dried product in an equal molar ratio in ~30
mL of water and stirred overnight. After this, the mixture is syringe filtered to remove
the silver chloride. The aqueous solution is evaporated to dryness to obtain the product.
Weight of silver oxalate to be added =
Obtained product of N, N, N, N tetramethylethylenediamine×Mass of silver Oxalate
Weight of Pt(Me4en)Cl2
D. Second Synthetic Method for Preparation of [Pt(Me4en)(Ox)]
56.5 mg of Pt(Me4en)I2 and 30 mg of silver oxalate is added to 30 ml of deionized
water. The product was dried in a rotovap to obtain [Pt(Me4en)(Ox)].
E. Synthesis of [Pt(en)(Ox)]
65.2 mg of platinum(II) ethylenediamine dichloride and 60 mg of silver oxalate
are added to 35 mL of water and allowed to stir for 24 hours. The product was gravity
filtered to remove any excess silver oxalate and dried in a rotovap to obtain [Pt(en)(Ox)].
F. Reactivity of [Pt(en)(Ox)] with 5'- GMP and N-AcMet
The reaction between the water soluble platinum compound [Pt(en)(Ox)], NAcMet and 5'-GMP was monitored at mole ratios of 1:1, 1:2 individually and
competitively at mole ratios of 1:2:1 and 1:4:1. Additionally 1.5 mL of D2O was added to
the amber vial. After keeping the pH around 4-5, the solution was transferred to an NMR
tube for NMR spectroscopy.
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G. Reactivity of [Pt(Me4en)(Ox)] with 5'- GMP and N-AcMet
The reaction between [Pt(Me4en)(Ox)], 5'-GMP and N-AcMet was followed at
mole ratios of 1:1, 1:2 individually and competitively at mole ratios of 1:2:1 and 1:1:2.
After keeping the pH around 4-5, the solution was transferred to an NMR tube for NMR
spectroscopy.
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III. RESULTS
The competition reactions between N
N-AcMet and 5'- GMP with [Pt(en)(Ox)] and
similarly with [Pt(Me4en)Ox] are studied quantitatively using 1H NMR at pH 4 at varying
concentrations.

Figure 11. Structure of [Pt(en)(Ox)]

Figure 12. Structure of [Pt(Me4en)(Ox)]
To begin, 10 mM [Pt(en)(Ox)] is added with 10 mM 5'-GMP. The pH is
determined
etermined and adjusted to 4. This reaction produced the following 1H NMR spectra
(Fig.13). The downfield shift of H8 reactivity signals at ~8.5 ppm, indicates the
significant reactivity of [Pt(en)(Ox)] with 5'-GMP via N7.

18

A. Reactivity of [Pt(en)(Ox)] w
with 5'-GMP at 1:1 Ratio

Figure 13. 1H NMR spectrum of [Pt(en)(Ox)] with 5'-GMP at 1:1 ratio
Each side of the NMR spectrum has the yy-axis
axis scaled to the largest peak to make
the signals
ignals easier to observe (Fig. 13). The 5'-GMP
GMP product signals are indicated by an
asterisk. The initial
nitial concentrations of each reactant are 10 mM.
When [Pt(en)(Ox)] and 5'-GMP at 1:1 ratio were combined
ed at pH 4, key
k NMR
resonances were observed within 24 hhours. The 5'-GMP H8 signals shifted downfield to
~8.5 ppm, indicating coordination of the platinum complex with 5'-GMP
GMP via N7 atom of
the guanine. Previously, it was shown that the [Pt(en)(D2O)2]+2 reactivity with 5'-GMP
results in two possible steps
steps. One is the reaction of diaqua complexes with the first
guanine ligand. The second is the reaction of the mono-product
product with a second guanine
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ligand.18 Here, in this reaction
reaction, when oxalates as a leaving ligand for
or Pt(en) are utilized,
utilized
only [Pt(en)(5'-GMP)2] is observed. The unreacted [Pt(en)(Ox)] indicates
es that the bisproducts are formed predominantly with the second 5'-GMP
MP addition being more rapid
than the first 5'-GMP.
B. Reactivity of [Pt(en)(Ox)] and 5'-GMP at 1:2 Ratio
We considered reactions between [Pt(en)(Ox)] and 5'-GMP at 24 hours, 48 hours,
and 72 hours. 500 µL aliquots of 10 mM [Pt(en)(Ox)] and 20 mM of 5'-GMP
GMP are
combined together at pH 4.(Fig.14) The reactivity of 5'-GMP with [Pt(en)(Ox)] was
observed within 24 hours
hours. The downfield shift of H8 signals at 8.5 ppm indicates the
coordination of platinum complex with 5'-GMP via N7.

Figure 14. 1H NMR spectrum of reactivity of [Pt(en)(Ox)] with 5'-GMP
GMP at 1:2 ratio.
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The 1:2 products formed from the reaction have key resonances at ~8.5 ppm.
Each side of the NMR spectrum has the y-axis scaled to the largest peak to make the
signals easier to observe. The product signals are indicated by an asterisk.
The 5'-GMP H8 signals shifted downfield at ~8.5 ppm indicates the coordination
of the platinum complex with 5'-GMP via N7 atom of the guanine. The predominant
bis-products are formed indicating the formation of the complex [Pt(en)(Ox)( 5'-GMP)2].
For both the molar ratios of 1:1 and 1:2 the [Pt(en)(Ox)] reacts with 5'-GMP. The
downfield chemical shift at ~8.5 ppm indicates the [Pt(en)(Ox)] reacts with 5'-GMP,
resulting in the formation of bis-products with two 5'-GMP substituted in a platinum
compound.
C. Reactivity of [Pt(en)(Ox)] with N-AcMet at 1:1 Ratio
N-AcMet was initially chosen because it has been utilized in similar studies and
because the methyl signal from the acetyl group provides another NMR signal that is
readily observable. 10 mM [Pt(en)(Ox)] and10 mM N-AcMet at 1:1 molar ratio are
combined. The pH is determined and adjusted to 4. The reaction was monitored at
intervals 1 hour, 24 hours, and 48 hours. The signal at ~2.5 ppm is a typical chemical
shift for the S-CH3 resonance of sulfur coordinated N-AcMet.26 The N-AcMet connects
to the pt(en) via sulfur.
Fig. 15 shows the 1H NMR spectrum of [Pt(en)(Ox)] and N-AcMet. The intensity
of the signals corresponding to a chemical shift of ~2.2 ppm and ~2.5 ppm increased as
the time of the reactivity increased.

21

Figure 15. 1H NMR spectrum of reactivity of [Pt(en)(Ox)] with N-AcMet
AcMet at 1:1 ratio
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The signal at~ 2.2 ppm, ~2.5 ppm is a typical chemical shift for the S-CH3
resonance of a sulfur coordinated N-AcMet.18,26 The signals from~ 2.1 ppm and ~2.3 ppm
are from unreacted N-AcMet. The amount of unreacted N-AcMet decreases only slightly
from 24 to 48 hours indicating the reaction between platinum and N-AcMet is mostly
complete after 24 hours.
Comparing the reactivity of N-AcMet with [Pt(en)(Ox)] to the reactivity of
[Pt(en)(Ox)] with 5'-GMP, the reaction of N-AcMet with [Pt(en)(Ox)] is faster and
shows the reactivity at 1 hour and is mostly complete within 24 hours. The reactivity with
5'-GMP is only partially complete after 24 hours. The results from Kung et al., indicated
a competitive situation between 5'-GMP and L-Methionine for coordinating oxaliplatin
and a favored coordination of L-Methionine.27 Consistent with the current study,
[Pt(en)(Ox)] reactivity with N-AcMet is faster when compared to the reactivity with 5'GMP. The oxalates are easily displaced with that of methionine residues and thus product
formation was observed quickly in hours rather than days as in the case of reaction of
[Pt(en)(Ox)]with 5'-GMP.
D. Reactivity of [Pt(en)(Ox)] with N-AcMet at 1:2 Ratio
10 mM [Pt(en)(Ox)] and 20 mM N-AcMet at 1:2 molar ratio were reacted at pH
4. The reaction was monitored at 1 hour, 24 hours, and 48 hours. The signals at ~2.2 ppm
and ~2.5 ppm are typical chemical shifts for the S-CH3 resonance of a sulfur coordinated
N-AcMet.26 The N-AcMet connects to the pt(en) via sulfur.
Fig. 16 shows the partial 1H NMR spectrum of 10 mM of [Pt(en)(Ox)] and 20
mM of N-AcMet at pH 4.0 after 1 hour and 24 hours. The products formed from the
reaction with [Pt(en)(Ox)] and N-AcMet has key resonances at ~2.2 ppm and ~2.5 ppm
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indicating the sulfur of methionine coordination with [Pt(en)(Ox)] and thus formation of
products.

Figure 16. 1H NMR spectrum of reactivity of [Pt(en)(Ox)] with N-AcMet
AcMet at 1:2 ratio.

24

Figure 17. 1H NMR spectrum of reactivity of [Pt(en)(Ox)] with N-AcMet
AcMet at 1:2 ratio
Fig. 17 highlights the N-AcMet S-CH3 signal shifted downfield to ~2.5 ppm
indicating the coordination of sulfur atom of methionine to platinum complexes.
complexes The
original S-CH3 signals of unreacted N
N-AcMet are around ~2.3 ppm, but the signal shifts
to ~2.5 ppm due to the reaction with the platinum compound. On thee basis of the previous
results 18, 26 we assigned the new sets of resonances that appeared to be [Pt(en)(N-AcMet[P
S)2].18
From the molar ratio 1:1
1:1-1:2 [Pt(en)(Ox)] reacts with N-AcMet. The signal
intensity at 2.5 ppm, indicate
indicates the S-CH3 connect with platinum and have two N-AcMet
N
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react with the platinum. The one major signal that is formed at ~2.5
2.5 ppm results in the
formation of bis-products
products [Pt(en)(N-AcMet-S)2]. (Fig.18)

Figure 18. Predicted Structure of Pt(en)(N
Pt(en)(N-AcMet-S)2 complex.
E. Reactivity of [Pt(en)(Ox)] w
with 5'-GMP and N-AcMet at 1:1:2 Ratio
500 µl aliquots of 10 mM of [Pt(en)(Ox)],, 10 mM 5’GMP, and 20 mM N-AcMet
N
are combined and the pH is adjusted to 44. The reactivity is interpreted by the 1H NMR
spectra after 24 hourss and 48 hours. (Fig.19)

Figure 19. 1H NMR spectrum of reactivity of [Pt(en)(Ox)] with 5'-GMP
GMP and N-AcMet
N
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The products formed from the reaction with 5'-GMP and N-AcMet have key
resonances at ~8.6 ppm and ~ 2.5 ppm respectively. (Fig.19).
The reactivity of [Pt(en)(Ox)] with 5'-GMP was slow after 24 hours and
remained similar in its intensity even after 48 hours. Product signals at ~8.6 ppm were
observed corresponding to [Pt(en)(N-AcMet-S)(5'-GMP-N7)] which indicates the
reaction of the platinum complex with guanine via N7 residues at 24 hour time. There
was significant amount of product formed for N-AcMet initially after 24 hours and
increased dramatically even after 48 hours. Also, there were more intense peaks observed
at ~2.5 ppm indicating the downfield shift of methionine with [Pt(en)(Ox)] at 48 hours.
The S-CH3 signal of [Pt(en)(N-AcMet-S)] occurs at ~2.5 ppm. As Fig. 19 indicates, more
products are initially formed with N-AcMet than with 5'-GMP. Throughout the reaction,
the amount of N-AcMet reacted exceeds the amount of 5'-GMP reacted. Within ~48
hours, signals due to [Pt(en)(N-AcMet-S)2] were observed. On the basis of previous
results,18,26 the final product from the studies are [Pt(en)(N-AcMet-S)(5'-GMP-N7)] and
a bis coordinated N-AcMet product [Pt(en)(N-AcMet-S)2]. Compared to the previous
results,18 the [Pt(en)(ox)] reacted quickly with N-AcMet than 5'-GMP.
F. Reactivity of [Pt(en)(Ox)] with 5'-GMP and N-AcMet at 1:4:1 Ratio
We modified the reactivity by adding 10 mM of [Pt(en)(Ox)] to 40 mM 5'-GMP
and 10 mM N-AcMet. 500 µl aliquots of each were mixed together and the pH was
determined. The reactivity is interpreted by 1H NMR spectra after 24 hours and 48 hours.
(Fig. 20).
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Figure 20. 1H NMR spectrum of reactivity of [Pt(en)(Ox)] with 5'-GMP
GMP and N-AcMet
The 1: 4 products formed from reaction with 5'-GMP and N-AcMet
cMet have key
resonances at ~8.5 ppm, ~ 8.6 ppm, and ~ 2.5 ppm respectively. (Fig. 20).
Four
our equivalents of 5'-GMP were added to one equivalent of [Pt(en)(Ox)] and
two equivalents of N-AcMet.
AcMet. When the reaction was monitored after 24 hours,
hour 48 hours,
and 72 hours, two key resonances at ~8.5 ppm and ~8.6 ppm were observed.
observed The
significant downfield shift of H8 atoms indicates N7 coordination of 5'-GMP
GMP. On the
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basis of the previous results,18,26 the products’ peaks can be interpreted. The intensity of
signals for N-AcMet increased from a 24 hour time period to a 72 hour time period. The
downfield shift of H8 signals at ~2.5 ppm corresponds to the N-AcMet bis-product
[Pt(en)(N-AcMet-S)2], which is due to a sulfur coordination with methionine. There are
also two products in the GMP range. At least one of the products that is left is due to
[Pt(en)(N-AcMet-S)(5'-GMP-N7)], whereas the other signal which corresponds to bis 5'GMP products on the right side is due to [Pt(en)(5'-GMP)2].
In comparison to the previous results,26 the products formed when four
equivalents of 5'-GMP were added to the one-to-one mixture of [Pt(en)(Ox)] and NAcMet are [Pt(en)(N-AcMet-S)2], [Pt(en)(N-AcMet-S)(5'-GMP-N7)] and [Pt(en)(5'GMP)2].
Bulky Compounds
The competition reactions between N-AcMet and 5'- GMP with [Pt(Me4en)(Ox)]
are studied quantitatively using 1H NMR at pH 4 at varying concentrations.
G. Reactivity of [Pt(Me4en)(Ox)] with 5'- GMP at 1:1 Ratio
The reactivity of [Pt(Me4en)(Ox)] with 5'-GMP is studied by the 1H NMR
spectroscopy. 500 µL aliquots of 10 mM of [Pt(Me4en)(Ox)] with 10 mM of 5'-GMP are
combined together and pH is adjusted to 4. The reactivity is interpreted by 1H NMR
spectra after 24 hours, 48 hours, and 72 hours respectively.
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Figure 21. 1H NMR spectrum of reactivity of [Pt(Me4en)(Ox)] with 5'-GMP
GMP at 1:1 ratio
The reactivity of 55'-GMP with [Pt(Me4en)(Ox)] is very slow. After 24 hours, there
was no significant amount of product signals formed from the reaction indicating that
there is no reactivity of 5''-GMP and hence no observance of new H8 signals.
gnals. After one
week, there were product signals formed, indicating the reactivity of 5'-GMP.
GMP. The
downfield shift of H8 signals at ~8.3 ppm indicates the coordination of platinum complex
with 5'-GMP via N7. [Pt(Me4 en)(Ox)] is the bulky compound, and its reactivity with 5'GMP was observed after oone week forming a predicted bis-products with two substituted
5'-GMP’s. The results which show the sslow reactivity of [Pt(Me4 en)(Ox)] with 5'-GMP
were consistent with the previous study which was conducted on [Pt(Me4 en)(D2O)2]+2.
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Analysis of rate constants of [Pt(Me4en)(D2O)2]+2 and [Pt(en)(D2O)2]+2 with 5'GMP’s from the previous papers have shown that [Pt(en)(D2O)2]+2 reacts about 13
times faster than [Pt(Me4en)(D2O)2]+2. 16 This could be due to several factors including
the steric bulk of Me4en ligand, hydrogen bonding to the NH2 groups in [Pt(en)(D2O)2]+2,
and possible trans effect differences due to reaction trans to an NH2 vs. an N(CH3)2 .We
conclude that the presence of bulky Me4en ligand slows the reaction with 5'-GMP’s.
Thus, the bulk factor hinder
hinders the reactivity of [Pt(Me4en)(Ox)] with 5'-GMP
GMP quickly.

H. Reactivity of [Pt(Me4en)(Ox)] with 5'
5'-GMP at 1:2 Ratio

Figure 22. 1H NMR spectrum of reactivity of [Pt(Me4en)(Ox)] with 5'-GMP
GMP at 1:2 ratio
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Fig. 22 shows the ppartial 1H NMR spectra from the reaction of 10 mM of
[Pt(Me4en)(Ox)] and 20 mM of 55'-GMP at pH 4.0. The products formed from the
reaction of [Pt(Me4en)(Ox)]
x)] and 55'-GMP have two key resonances at ~8.3 ppm. The
product signals for reactivity of 5'
5'-GMP
GMP are not observed after one week. The above
NMR spectrum scaled to the largest peak to make the signals easier to observe.

Figure 23. 1H NMR spectrum of reactivity of [Pt(Me4en)(Ox)] with 5'-GMP
GMP showing bisbis
products
Fig. 23 shows the ppartial 1H NMR spectra of bis-products’ formation between
[Pt(Me4en) (Ox)] and 5'-GMP
GMP at 8.3 ppm. Product signals were observed after 5 days of
reactivity.
We modified the previous reactivity with two equivalents of 5'-GMP
GMP and
monitored from 24 hours to 10 days. H8 signals shifted downfield at ~8.3
3 ppm indicating
the N7 coordination of 5'--GMP after 5 days. Previously, it was found that when
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[Pt(Me4en)(D2O)]2 reacted with 5'-GMP results in two possible steps one is that the
reaction of diaqua complexes with the first guanine ligand. The second is the reaction of
the mono-product with a second guanine ligand.18 Here, in this reaction when oxalates as
a leaving ligands for Pt(Me4en) are utilized only [Pt(Me4en)(5'-GMP)2] is observed. The
reactivity of [Pt(Me4en)(Ox)] with 5'-GMP was comparatively slow when compared to
[Pt(en)(Ox)]. The Me4en bulk slowed the reactivity with 5'-GMP and took days to
complete the reaction. (Fig. 21), (Fig. 22).
I. Reactivity of [Pt(Me4en)(Ox)] with N-AcMet at 1:2 Ratio
500 µL aliquots of 10 mM of [Pt(Me4en)(Ox)] with 20 mM of N-AcMet were
combined together, and reacted at pH 4; the reactivity is interpreted by the 1H NMR
spectra after 1 hour, 24 hours, and 48 hours respectively.
A signal at ~2.5 ppm was assigned to the S-CH3 signal. The downfield shift of SCH3 signals indicates the sulfur coordination with methionine. (Fig 24). On the basis of
comparison of previous results,20,26 we assigned the new sets of resonances that appeared
to be at ~2.5 ppm which corresponds to [Pt(Me4en)(N-AcMet-S)(ox-O)](mono
coordinated) and a signal at ~2.6 ppm which corresponds to [Pt(Me4en)(N-AcMet-S,
O)+](sulfur-oxygen chelate).
Formation of the complex [Pt(Me4en)(N-AcMet-S, O)+] appeared to be
significantly faster than the formation of 5'-GMP complex as evidenced by the extent of
reaction of each at 24 hours. When N-AcMet is added to the bulky platinum complex the
oxalates are easily displaced within 24 hours to 48 hours of reactivity. The N-AcMet
product is formed at 1 hour and a significant increase in the intensity of product signals at
48 hours was observed.

33

The following 1H NMR spectrum shows the reactivity of [Pt(Me4en)(ox)] with NAcMet

Figure 24. 1H NMR spectrum of reactivity of [Pt(Me4en)(Ox)] with N-AcMet
AcMet at 1:2
J. Reactivity of [Pt(Me4 en)(
en)(Ox)] and N-AcMet at 1:1 Ratio
500 µL aliquotss of 10 mM of [Pt(Me4en) (ox)] with 10 mM of N-AcMet
N
are
combined together and pH is adjusted to 4. T
The
he reactivity is interpreted by the 1H NMR
spectroscopy after 1 hour, 24 hours
hours, and 48 hours respectively.
A signal at ~2.5
2.5 ppm was assigned to the S-CH3 signal; such a downfield
chemical shift is similar to that observed at 1:2 ratio. On the basis of comparison of
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previous results,20,26 we assigned the new sets of resonances that appeared to be at ~2.5
ppm which corresponds to [Pt(Me4en)(N-AcMet-S)(ox-O)](mono-coordinated) and a
signal at ~2.6 ppm corresponds to [Pt(Me4en)(N-AcMet-S, O)+](sulfur-oxygen chelate).
The signals at ~2.0 ppm and ~2.1 ppm correspond to the unreacted N-AcMet. The
intensity of product signals at ~2.5ppm for S-CH3 increases dramatically from 1 hour to
48 hours.
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Figure 25. 1H NMR spectrum of reactivity of [Pt(Me4en)(Ox)] with 5'-GMP
GMP at 1:1 ratio.
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K. Reactivity of [Pt(Me4 en
en)(Ox)] With N-AcMet And 5'-GMP
GMP at 1:2:1 Ratio
R
500 µL aliquots of 10 mM of [Pt(Me4en) (ox)] with 20 mM of N--AcMet and 10
mM of 5'-GMP are combined together at pH 4. The reactivity is interpreted by the 1H
NMR spectra.

Figure 26. 1H NMR spectrum of reactivity of [Pt(Me4en)(Ox)] with 5'-GMP
5'
and NAcMet.
We monitored the reactivity by conducting competition studies between
[Pt(Me4en)(Ox)], 5'-GMP
GMP, and N-AcMet and see if 5'-GMP could displace N-AcMet.
N
We
expected
ted that the second Pt
Pt-O bond is easier to displace after the first Pt-O
O bond is broken
which means N-AcMet
AcMet reacts first to break the oxalate chelate then the 5'-GMP
5'
displaces
the unidentate oxalate ligand; thus [Pt(Me4en )(N-AcMet-S)( 5'-GMP)
GMP) was a possible
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product. 26 According to the previous studies conducted, the mixed ligand complexes
would not have severe steric clashes.27 The intensity of product peaks increased as the
time increased resulting in the predicted product formation at ~8.8 ppm corresponding to
[Pt(Me4en)(N-AcMet)( 5'-GMP-N7)] but is not due to [Pt(Me4en)( 5'-GMP)2].27 The
significant downfield shift of the H8 atom indicates N7 coordination of 5'-GMP.
Likewise, the S-CH3 signal at ~2.4 ppm which corresponds to [Pt(Me4en)(Ox)(N-AcMetS, O)]+. The 1H NMR signals did not disappear even after several days and [Pt(Me4en)(
5'-GMP)2] signals appeared, indicating complete displacement of N-AcMet did not occur.
L. Reactivity of [Pt(Me4 en)(Ox)] with 5'-GMP and N-AcMet at 1:1:2 Ratio
We modified the reactivity by adding one equivalent of [Pt(Me4en)(Ox)] with one
equivalent of N-AcMet and 2 equivalent of 5'-GMP. After 24 hours, new signals were
observed in the NMR spectrum. A new resonance in the H8 region of the spectrum was
observed at ~8.8 ppm suggesting it is due to [Pt(Me4en) (N-AcMet)( 5'-GMP)]+. The
significant downfield shift of the H8 atom indicates N7 coordination of 5'-GMP.
Likewise, the S-CH3 signals at ~2.4 ppm corresponds to [Pt(Me4en) (N-AcMet-S, O)+2].
The 1H NMR signals did not disappear even after several days and no
[Pt(Me4en)(5’GMP)2] signals appeared indicating the complete displacement of N-AcMet
did not occur.
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Figure 27. 1H NMR spectrum of reactivity of [Pt(Me4en)(Ox)] with 5'-GMP
5'
and NAcMet
We conclude from Fig
Fig. 26 and Fig. 27
7 that the significant downfield shift of H8
atom indicates N7 coordination of 5'-GMP and the predicted possible product formed
was [Pt(Me4en) (N-AcMet)(
AcMet)( 5'-GMP)]+.
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IV. DISCUSSION
In the current research the main focus is to check the reactivity of platinum
complexes with guanine residues of DNA and methionine residues of proteins. Although
the reaction with DNA is thought to be responsible for the anticancer activity, the
reaction of platinum complexes with proteins is significant. It is suggested that protein
binding contributes to the toxicity of platinum anticancer drugs; however, the reactivity
of platinum with biological thiols may be a pathway for detoxification and resistance.26
Therefore, better understanding of the interactions of platinum complexes with DNA and
protein targets is important. With platinum being a soft metal, the sulfur atoms of
methionine and cysteine residues are the primary targets in proteins.26
Due to the high affinity of platinum(II) compounds to sulfur, sulfur containing
molecules are frequently applied as rescue agents in cancer therapy. According to the
previous investigations, mixed-ligand adducts formation is possible because of reversible
methionine binding during the reaction of cisplatin with 5'-GMP in the presence of LMethionine.28 According to the Kung et al., the addition of L-Methionine at the
physiological concentration results in an increase of the rate of complex formation at the
initial step of the reaction and different adduct formation for the reaction with
carboplatin, cis-[Pt(NH3)2(HM)], and cis-[Pt(NH3)2(M)].28 Oxaliplatin reacts faster with
5’-GMP, and, contrary to the ammine ligands of the other complexes, the DACH ligand
cannot be released.28,30 Formation of the chelate is favored in the presence of equimolar
amounts of 5'-GMP and L-Met and the displacement of L-Met by 5’-GMP cannot be
observed.28 These results indicate the correlation with our observations that 5'-GMP
displaces oxalate ligands very slowly.
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Platinum connectivity with sulfur is generally favored when compared to nitrogen
and oxygen because platinum is a low electro negativity element and has a low energy
LUMO. To differentiate sulfur from nitrogen and oxygen, sulfur has a large atomic
radius, higher polarizability, and lower electro negativity than nitrogen and oxygen.
Sulfur is also a soft base when compared to nitrogen and oxygen. According to HSAB
theory, soft Lewis acids react faster and form stronger bonds with soft bases. Therefore,
platinum connectivity with sulfur is more favored than with oxygen and nitrogen.
In the current study, reactivities of [Pt(en)(Ox)] and [Pt(Me4en)(Ox)] with 5'GMP individually and in the presence of N-AcMet in 1:1 and 1:2 ratios at pH 4 are
quantitatively studied using 1H NMR spectroscopy. We used oxalates as leaving ligands
because we wanted to see how the difference in the leaving ligand affected the reactivity
of platinum complexes; the oxalate leaving ligand is utilized in the third generation
anticancer drug oxaliplatin. We kept the pH at ~4 in order to keep the 5'-GMP phosphate
group from completely deprotonating.
The reactivity of [Pt(en)(Ox)] with 5'-GMP and N-AcMet is faster when
compared with the bulkier complex [Pt(Me4 en)(Ox)]. Previously, it was shown that the
[Pt(en)(D2O)]2+ reacted 13 times faster with 5'-GMP than [Pt(Me4 en)(D2O)]2+.18 The
possible reasons for the slow reactivity of [Pt(Me4 en)(D2O)]2+ were due to several factors
including steric bulk of the Me4en ligand, hydrogen bonding to the NH2 groups in [Pt(
en)(D2O)]2, and possible trans effect differences due to the reaction trans to an NH2 vs.
an N(CH3)2 group. The current studies showed very slow reactivity of 5'-GMP with
[Pt(Me4en)(Ox)]. After one week, two small downfield shifted H8 signals were observed,
indicating the coordination of N7 residues with guanine. Thus, from these studies it can
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be concluded the steric bulk of Me4en hindered the reactivity quickly when compared to
en complex.
A previous study found that both platinum complexes [Pt(en)(D2O)2]+2 and
[Pt(Me4en)(D2O)]+2 reacted faster with 5'-GMP. The possible explanation for its
reactivity is due to the hydrogen bonding with a 5' phosphate and that the en ligand
would not have any steric clashes with an incoming ligand.18 The reactivity is explained
in two possible steps: the reaction of the diaqua complexes with the first guanine ligand,
and the reaction of the mono product with the second guanine ligand. Although the
reaction conditions utilized the favored formation of a mono-product, a mechanism to
account for further reactions to bis-products was used.18 However, in the current study
the reactions of the platinum complexes [Pt(en)(Ox)] and [Pt(Me4en)(Ox)] with 5'-GMP
result in the formation of bis-products with no intermediates. It indicates the second 5'GMP reacts faster than the first, since the first 5'-GMP has to break the oxalate chelate.
The bis-products formed are [Pt(en(5'-GMP)2] and [Pt(Me4en)(5'-GMP)2].
The scheme of the possible reactions of [Pt(en)(Ox)] and [Pt(Me4en)(Ox)] with
5'-GMP is explained in Fig 28 and Fig 29
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Figure 28.. Scheme of reactions of [Pt(en)(Ox)] with 5'-GMP
GMP
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Figure 29. Scheme of reactions of [Pt(Me4en)(Ox)] with 5'-GMP
GMP
The [Pt(en)(Ox)]] rreactivity with N-AcMet
AcMet was favored more quickly at a 1:2
molar ratio, and a new product, [Pt(en)(N-AcMet-S)2], is formed. Previously, during the
reactions between [Pt(en)(D2O)2]+2 and N-AcMet, several products were observed.
observed In
addition to the mono-substituted
substituted product, an intermediate Pt(en)(N-AcMet
AcMet-S)(D2O)]+ and
bis-products [Pt(en)(N-AcMet
AcMet-S)2] are also formed.18 When oxalates as leaving ligands
are used only a bis substituted N
N-AcMet is formed with no intermediates..
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Figure 30. Scheme of reactions of [Pt(en)(Ox)] with N
N-AcMet
AcMet
Our previous study found that the [Pt(Me4en)(D2O)2]2+ complex reacted with
only one N-acetyl
acetyl methionine residue to form S, O chelates.18 Molecular mechanics
calculations suggested that a [Pt(Me4en)(Met-S)2]2+ complex would have severe steric
clashes regardless of the chiralities of the sulfur atoms or the relative orientations of the
methionine residues. Also, the bulk prevented coordination of the amide nitrogen of an
N-acetyl
acetyl methionine residue.18 The possible explanation for the faster reactivity of
[Pt(Me4 (en)Ox)] with N--AcMet than with 5’-GMP
GMP in the current study could be due to
the easier replacement of oxalate ligands by methionine residues than by guanine
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residues. The possible products formed when N
N-AcMet
cMet reacted with [Pt(Me4 en)(Ox)] are
[Pt(Me4 en) (N-AcMet-S,
S, O)]+ as well as the mono-substituted N-AcMet
AcMet product [Pt(Me4
en)(Ox-o)(N-AcMet-S]+

Figure 31. Scheme of reactions of [Pt(Me4 (en)Ox)] with N-AcMet
AcMet
Previously, by using capillary electrophoresis
electrophoresis-electospray
electospray ionization-mass
ionization
spectrometry (CE-ESI-MS)
MS), the binding behavior of oxaliplatin to 5'-GMP
GMP in the
presence of the sulfur containing amino acid L
L-methionine
methionine was investigated.27, 31 The
results from Kung et al, indicated a competitive situation between 5'-GMP
GMP and LMethionine for coordinating
dinating oxaliplatin and a favo
favored coordination of L-Methionine.
Consistent with the current study
study, [Pt(en)(Ox)] reactivity with N-AcMet
AcMet is faster
when compared to the reactivity wi
with 5'-GMP.
GMP. The oxalates are easily displaced
displa
by
methionine residues,, and product formation was observed quickly in hours rather than
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days as in the case of reaction with 5'-GMP. Also, when competitive studies between
[Pt(en)(Ox)] with N-AcMet
AcMet and 5'-GMP were investigated using 1H NMR,
NMR The
predominant products formed were [Pt(en)(N-AcMet-S)2], [Pt(en)(N-AcMet
AcMet-S)(5'-GMPN7)] and [Pt(en)(5'-GMP)
GMP)2.

Figure 32. Scheme of reactions of [Pt(en)(Ox)] with N
N-AcMet
AcMet and 5'-GMP
5'
When [Pt(Me4 en)(Ox)], N
N-AcMet, 5'-GMP were added together, a new resonance
in the H8 region of the spectrum was observed at ~8.8 ppm corresponding
ing to [Pt(Me4en)
(N-AcMet)( 5'-GMP)]+.
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Figure 33. Scheme of reactions of [Pt(Me4en)(Ox)] with N-AcMet
AcMet and 5'-GMP
5'
When [Pt(Me4en)(Ox)] reacted with N-AcMet and 5'-GMP the predictable
products formed were [Pt(Me4 en)(Ox)(N-AcMet-S)]+ and [Pt(Me4en) (N-AcMet)(
(N
5'GMP)]+.
It was found that the oxalate leaving ligand slowed the reactivity more with 5'GMP when compared to N
N-AcMet. The reaction rate with 5'-GMP was faster when NN
AcMet was added simultaneously to the mixture of platinum complex and 5'-GMP. This
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result suggests that the N-AcMet reacts first to break the oxalate chelate, then the 5'-GMP
displaces the unidentate oxalate ligand.
In summary, we have utilized a 1H NMR spectroscopy to study the reactivity of
platinum(II) diamine complexes [utilizing [Pt(en)(Ox)] as a non bulky complex and
[Pt(Me4 en)(Ox)] as a bulky complex] with 5'-GMP and N-AcMet individually and
competitively. The reactivity of [Pt(en)(Ox)] and [Pt(Me4 en)(Ox)] with 5'-GMP resulted
in the bis-products with two substituted 5'-GMPs. The reactivity of [Pt(Me4 en)(Ox)] with
5'-GMP was very slow comparatively with [Pt(en)(Ox)]. Bis-products such as [Pt(en)(NAcMet-S)2] are predominantly formed when [Pt(en)(Ox)] reacts with N-AcMet. When
[Pt(Me4 en)(Ox)] reacts with N-AcMet two products are possible: one is [Pt(Me4 en) (NAcMet-S, O)]+, the other is [Pt(Me4 en)(Ox-o)(N-AcMet-S]+. When competition studies
of [Pt(en)(Ox)] with 5'-GMP and N-AcMet were conducted, the possible products formed
were [Pt(en)(N-AcMet-S)(5'-GMP-N7)] and [Pt(en)(5'-GMP)2]. Reactivity of
[Pt(Me4en)(Ox)] with N-AcMet and 5'-GMP resulted in [Pt(Me4en )(N-AcMet-S)( 5'GMP)]. The significant formation of [Pt(en)(N-AcMet-S)(5'-GMP-N7)] and[Pt(Me4en
)(N-AcMet-S)( 5'-GMP)] product indicates that N-AcMet reacts first to break the oxalate
chelate then the 5'-GMP displaces the unidentate oxalate ligand;
Future studies will focus on the product of the reaction at different pH levels and
time differences. Focus on studying the reactivity of platinum (II) complexes with
oxalates as leaving ligands at pH-7 is important as there is less chance of dimerization
reactions. Study of the reactivity of platinum(II) complexes with other amino acids like
histidine and cysteine will also be pursued.
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